A Phase 3 interventional study of LY2963016 and Lantus in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 62 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-18.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment of the 175 interventional ones that give a count, is one of 11 that started in 2011, is one of 60 in phase 3, and was the 94th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 759 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 39th largest by enrollment of the 232 interventional ones that give a count, is one of 22 that started in 2011, is one of 85 in phase 3, and was the 69th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) \[alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)\] administered per standard of care for 24 weeks
Drug: LY2963016 · Drug: OAMs
Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks
Drug: Lantus · Drug: OAMs
Administered subcutaneously
Administered subcutaneously
Administered orally
Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection and treatment.
Time frame: Baseline, Endpoint (up to 24 weeks)
Change From Baseline in Insulin Antibody Levels
Blood samples are collected from participants and percentage of insulin antibody binding measured. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline of response and treatment.
Time frame: Baseline and 4 weeks and 12 weeks and Endpoint (24 weeks and up to 24 weeks)
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection and treatment.
Time frame: Baseline and 4 weeks and 8 weeks and 12 weeks and 16 weeks and 20 weeks and 24 weeks
7-Point Self-Monitored Blood Glucose (SMBG) Profiles
Seven-point SMBG are completed at the following timepoints: Morning (AM) Pre-Meal, Morning (AM) Post-Prandial (PP), Midday (MD) Pre-Meal, Midday PP, Evening (EV) Pre-Meal, Bed Time and 0300 hours. PP glucose is measured 2 hours (hrs) after the start of the meal. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
Time frame: Baseline and Endpoint [up to 24 weeks (wk)]
Glycemic Variability of Fasting Blood Glucose
Glycemic variability is measured by the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning pre-meal blood glucose value from the 7-point self-monitoring blood glucose \[SMBG\] profiles. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
Time frame: Baseline and Endpoint (up to 24 weeks)
Change From Baseline in Body Weight
Change from baseline in body weight. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
Time frame: Baseline and 4 weeks (wk) and 8 wk and 12 wk and 16 wk and 20 wk and 24 wk and Endpoint (up to 24 wk)
Adult Low Blood Sugar Survey (ALBSS)
ALBSS contains 33 items, with each item scored on a 5-point response scale: 0 (never) to 4 (almost always). Items are categorized in 2 domains: Behavior (or avoidance) Items 1 to 15 and Worry (or affect) Items 16 to 33. Behavior Total Score range is 0 to 60 and Worry Total Score range is 0 to 72. Higher scores on "Behavior" items (related to avoidance of hypoglycemia) reflect greater awareness and/or effort of the participant to prevent low blood sugar. Higher scores on "Worry" items (related to worries about low blood sugar and its consequences) reflect greater participant concern about having low blood sugar. The ALBSS Total Scores (Worry and Behavior item scores combined) range is 0 to 132. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
Time frame: 4 weeks (wk) and 12 wk and Endpoint (up to 24 wk)
Insulin Treatment Satisfaction Questionnaire (ITSQ)
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. Least Squares (LS) mean are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
Time frame: 4 weeks (wk) and 12 wk and Endpoint (EP) (up to 24 wk)
Insulin Dose Per Body Weight (U/kg) Per Day
Insulin dose in units (U) per body weight in kilograms (kg) per day. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
Time frame: Endpoint (up to 24 weeks)
Insulin Dose (Units)
Units of insulin taken daily. Least Square (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1C, country, sulfonylurea use, time of basal insulin injection and treatment.
Time frame: Endpoint (up to 24 weeks)
Percentage of Participants With HbA1c <7 % and HbA1c ≤6.5%
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Baseline and 4 weeks and 8 weeks and 12 weeks and 16 weeks and 20 weeks and 24 weeks and Endpoint (up to 24 weeks)
Incidence of Hypoglycemic Events
A hypoglycemic event is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose (BG) concentration of ≤70 milligrams/deciliter (mg/dL) even if it was not associated with signs, symptoms, or treatment consistent with current American Diabetes Association (ADA: 2005) guidelines. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions (these episodes may be associated with sufficient neuroglycopenia to induce seizure or coma; also, BG measurements may not be available during such an event). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.
Time frame: Baseline and Endpoint (up to 24 weeks)
Rate Per 30 Days of Hypoglycemic Events
The rate of hypoglycemic events per 30 days between two visits is defined as the total number of events between the visits divided by the actual number of days between the visits, and then multiplied by 30 days. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.
Time frame: Baseline, Endpoint (up to 24 weeks)
Percentage of Participants With Detectable Insulin Antibody Levels
Time frame: Baseline and 4 weeks and 12 weeks and 24 weeks and Endpoint (up to 24 weeks) and Baseline to 24 weeks (Overall)
Percentage of Participants With Treatment Emergent Antibody Response (TEAR)
TEAR is defined as an absolute increase of at least 1% in insulin antibody levels (measured in % binding) and at least 30% relative increase from Baseline for participants who are insulin antibody-positive at Baseline, or turning from insulin antibody-negative status at Baseline to antibody-positive during the course of the study following treatment with study drug.
Time frame: 4 weeks and 12 weeks and 24 weeks and Endpoint (up to 24 weeks) and Baseline to 24 weeks (Overall)
| Milestone | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Started | 379 | 380 |
| Received at least 1 dose of study drug | 376 | 380 |
| Completed | 334 | 328 |
| Not completed | 45 | 52 |
| Withdrew: Adverse event | 6 | 10 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Lost to follow-up | 8 | 9 |
| Withdrew: Physician decision | 9 | 9 |
| Withdrew: Protocol violation | 8 | 5 |
| Withdrew: Withdrawal by subject | 12 | 16 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection and treatment.
| percentage of glycosylated hemoglobin | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c) | -1.286 ± 0.06 | -1.338 ± 0.06 |
Blood samples are collected from participants and percentage of insulin antibody binding measured. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline of response and treatment.
| percentage of insulin antibody binding | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Change at 4 weeks (n=10, 3) | -1.07 ± 1.47 | -3.25 ± 2.79 |
| Change at 12 weeks (n=9, 5) | -1.57 ± 1.14 | -4.39 ± 1.54 |
| Change at 24 weeks (n=10, 2) | -2.61 ± 0.60 | -3.21 ± 1.35 |
| Change at Endpoint, up to 24 weeks (n=14, 6) | -2.49 ± 0.39 | -3.11 ± 0.06 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection and treatment.
| percentage of HbA1c | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Change at 4 weeks (n=368, 371) | -0.452 ± 0.03 | -0.481 ± 0.03 |
| Change at 8 weeks (n=359, 358) | -0.871 ± 0.05 | -0.866 ± 0.05 |
| Change at 12 weeks (n=349, 351) | -1.134 ± 0.06 | -1.143 ± 0.06 |
| Change at 16 weeks (n=345, 345) | -1.265 ± 0.06 | -1.321 ± 0.06 |
| Change at 20 weeks (n=338, 334) | -1.294 ± 0.06 | -1.379 ± 0.06 |
| Change at 24 weeks (n=331, 329) | -1.336 ± 0.06 | -1.438 ± 0.06 |
Seven-point SMBG are completed at the following timepoints: Morning (AM) Pre-Meal, Morning (AM) Post-Prandial (PP), Midday (MD) Pre-Meal, Midday PP, Evening (EV) Pre-Meal, Bed Time and 0300 hours. PP glucose is measured 2 hours (hrs) after the start of the meal. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
| millimoles per liter (mmol/L) | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Baseline- AM Pre-Meal (n=353, 359) | 8.82 ± 0.13 | 8.86 ± 0.13 |
| Baseline- AM 2 hrs PP (n=356, 356) | 11.68 ± 0.16 | 11.80 ± 0.16 |
| Baseline- MD Pre-Meal (n=357, 357) | 9.09 ± 0.15 | 9.44 ± 0.15 |
| Baseline- MD 2 hrs PP (n=357, 353) | 10.65 ± 0.15 | 10.89 ± 0.15 |
| Baseline- EV Pre-Meal (n=356, 354) | 9.29 ± 0.15 | 9.59 ± 0.15 |
| Baseline- Bed Time (n=355, 354) | 11.25 ± 0.16 | 11.17 ± 0.16 |
| Baseline- 0300 hrs (n=342, 341) | 8.83 ± 0.15 | 8.96 ± 0.15 |
| Endpoint, up to 24 wk- AM Pre-Meal (n=353, 359) | 5.94 ± 0.11 | 6.06 ± 0.11 |
| Endpoint, up to 24 wk- AM 2 hrs PP (n=356, 356) | 8.07 ± 0.17 | 8.40 ± 0.17 |
| Endpoint, up to 24 wk- MD Pre-Meal (n=357, 357) | 6.81 ± 0.15 | 7.12 ± 0.15 |
| Endpoint, up to 24 wk- MD 2 hrs PP (n=357, 353) | 8.53 ± 0.17 | 8.69 ± 0.18 |
| Endpoint, up to 24 wk- EV Pre-Meal (n=356, 354) | 7.29 ± 0.16 | 7.40 ± 0.16 |
| Endpoint, up to 24 wk- Bed Time (n=355, 354) | 8.56 ± 0.18 | 8.67 ± 0.18 |
| Endpoint, up to 24 wk- 0300 hrs (n=342, 341) | 6.72 ± 0.15 | 6.70 ± 0.15 |
Glycemic variability is measured by the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning pre-meal blood glucose value from the 7-point self-monitoring blood glucose \[SMBG\] profiles. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
| millimoles per liter (mmol/L) | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Baseline | 1.18 ± 0.05 | 1.20 ± 0.05 |
| Endpoint, up to 24 weeks | 0.81 ± 0.06 | 0.79 ± 0.06 |
Change from baseline in body weight. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
| kilogram (kg) | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Change at 4 wk (n=361, 364) | 0.292 ± 0.11 | 0.526 ± 0.11 |
| Change at 8 wk (n=358, 357) | 0.999 ± 0.16 | 1.152 ± 0.16 |
| Change at 12 wk (n=350, 352) | 1.271 ± 0.19 | 1.440 ± 0.19 |
| Change at 16 wk (n=342, 344) | 1.550 ± 0.22 | 1.918 ± 0.22 |
| Change at 20 wk (n=340, 333) | 1.734 ± 0.25 | 2.234 ± 0.25 |
| Change at 24 wk (n=335, 329) | 1.914 ± 0.27 | 2.175 ± 0.27 |
| Change at Endpoint, up to 24 wk (n=370, 374) | 1.776 ± 0.25 | 2.020 ± 0.25 |
ALBSS contains 33 items, with each item scored on a 5-point response scale: 0 (never) to 4 (almost always). Items are categorized in 2 domains: Behavior (or avoidance) Items 1 to 15 and Worry (or affect) Items 16 to 33. Behavior Total Score range is 0 to 60 and Worry Total Score range is 0 to 72. Higher scores on "Behavior" items (related to avoidance of hypoglycemia) reflect greater awareness and/or effort of the participant to prevent low blood sugar. Higher scores on "Worry" items (related to worries about low blood sugar and its consequences) reflect greater participant concern about having low blood sugar. The ALBSS Total Scores (Worry and Behavior item scores combined) range is 0 to 132. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
| units on a scale | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Behavior Score- 4 wk (n=351, 354) | 8.41 ± 0.63 | 8.64 ± 0.64 |
| Behavior Score- 12 wk (n=350, 349) | 8.95 ± 0.62 | 9.36 ± 0.62 |
| Behavior Score- Endpoint up to 24 wk (n=368, 371) | 7.90 ± 0.60 | 8.36 ± 0.60 |
| Worry Score- 4 wk (n=352, 354) | 7.74 ± 0.91 | 8.82 ± 0.92 |
| Worry Score- 12 wk (n=349, 348) | 8.35 ± 0.91 | 8.51 ± 0.91 |
| Worry Score- Endpoint up to 24 wk (n=368, 371) | 8.61 ± 0.89 | 8.57 ± 0.90 |
| ALBSS Total Score- 4 wk (n=352, 354) | 16.15 ± 1.29 | 17.45 ± 1.29 |
| ALBSS Total Score- 12 wk (n=349, 348) | 17.32 ± 1.32 | 17.85 ± 1.32 |
| ALBSS Total Score-Endpoint up to 24 wk (n=368,371) | 16.53 ± 1.32 | 16.92 ± 1.33 |
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. Least Squares (LS) mean are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
| units on a scale | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| IR- 4 wk (n=352, 354) | 86.10 ± 1.24 | 86.12 ± 1.25 |
| IR- 12 wk (n=350, 348) | 83.44 ± 1.25 | 84.54 ± 1.25 |
| IR- EP, up to 24 wk (n=368, 371) | 85.62 ± 1.31 | 85.21 ± 1.32 |
| LF- 4 wk (n=352, 354) | 79.65 ± 1.55 | 79.87 ± 1.55 |
| LF-12 wk (n=350, 350) | 76.69 ± 1.52 | 78.16 ± 1.52 |
| LF- EP, up to 24 wk (n=368, 372) | 78.00 ± 1.51 | 78.32 ± 1.52 |
| HC- 4 wk (n=352, 354) | 79.36 ± 1.46 | 80.33 ± 1.46 |
| HC- 12 wk (n=350, 348) | 77.15 ± 1.49 | 77.73 ± 1.49 |
| HC- EP, up to 24 wk (n=368, 372) | 77.51 ± 1.54 | 79.08 ± 1.55 |
| GC- 4 wk (n=352, 354) | 75.67 ± 1.62 | 75.47 ± 1.63 |
| GC- 12 wk (n=350, 347) | 78.95 ± 1.53 | 81.38 ± 1.53 |
| GC- EP, up to 24 wk (n=368, 372) | 80.74 ± 1.53 | 80.26 ± 1.54 |
| IDD- 4 wk (n=352, 353) | 70.56 ± 1.56 | 73.22 ± 1.56 |
| IDD- 12 wk (n=348, 349) | 70.97 ± 1.70 | 72.21 ± 1.69 |
| IDD- EP, up to 24 wk (n=368, 372) | 72.85 ± 1.63 | 73.87 ± 1.64 |
| ITSQ Overall Total- 4 wk (n=352, 354) | 78.02 ± 1.12 | 78.98 ± 1.12 |
| ITSQ Overall Total- 12 wk (n=349, 348) | 77.06 ± 1.21 | 78.30 ± 1.20 |
| ITSQ Overall Total- EP, up to 24 wk (n=368, 372) | 78.54 ± 1.21 | 79.06 ± 1.22 |
Insulin dose in units (U) per body weight in kilograms (kg) per day. Least Squares (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1c, country, sulfonylurea use, time of basal insulin injection, and treatment.
| units per kilogram per day (U/kg/day) | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Insulin Dose Per Body Weight (U/kg) Per Day | 0.500 ± 0.03 | 0.479 ± 0.03 |
Units of insulin taken daily. Least Square (LS) means are determined by analysis of covariance (ANCOVA) and adjusted for Baseline HbA1C, country, sulfonylurea use, time of basal insulin injection and treatment.
| units per day (U/day) | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Insulin Dose (Units) | 44.465 ± 2.62 | 41.015 ± 2.61 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.
| percentage of participants | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| HbA1c- at Baseline < 7.0 % (n=369, 375) | 6.2 | 7.2 |
| HbA1c- at Baseline ≤ 6.5% (n=369, 375) | 3.5 | 2.4 |
| HbA1c- at 4 weeks < 7% (n=368, 371) | 16.6 | 15.4 |
| HbA1c- at 4 week ≤ 6.5%(n=368, 371) | 5.7 | 5.9 |
| HbA1c- at 8 weeks < 7% (n=359, 358) | 27.0 | 29.9 |
| HbA1c- at 8 weeks ≤ 6.5% (n=359, 358) | 10.3 | 14.5 |
| HbA1c- at 12 weeks <7% (n=349, 351) | 39.3 | 43.0 |
| HbA1c- at 12 weeks ≤ 6.5% (n=349, 351) | 20.3 | 22.8 |
| HbA1c- at 16 weeks <7% (n=345, 345) | 46.7 | 52.8 |
| HbA1c- at 16 weeks ≤ 6.5% (n=345, 345) | 24.3 | 28.4 |
| HbA1c- at 20 weeks < 7% (n=338, 334) | 49.4 | 54.2 |
| HbA1c- at 20 weeks ≤ 6.5% (n=338, 334) | 26.6 | 32.6 |
| HbA1c- at 24 weeks < 7% (n=331, 329) | 50.8 | 55.9 |
| HbA1c- at 24 weeks ≤ 6.5% (n=331, 329) | 27.5 | 32.5 |
| HbA1c- Endpoint, up to 24 weeks <7% (n=369, 375) | 48.8 | 52.5 |
| HbA1c- Endpoint, up to 24 weeks ≤ 6.5% (n=369,375) | 26.8 | 30.4 |
A hypoglycemic event is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose (BG) concentration of ≤70 milligrams/deciliter (mg/dL) even if it was not associated with signs, symptoms, or treatment consistent with current American Diabetes Association (ADA: 2005) guidelines. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions (these episodes may be associated with sufficient neuroglycopenia to induce seizure or coma; also, BG measurements may not be available during such an event). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.
| hypoglycemic events in 24 weeks | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Total Events with BG ≤70 mg/dL | 3564 | 3845 |
| Severe Events | 7 | 2 |
| Nocturnal Events with BG ≤70 mg/dL | 1248 | 1386 |
The rate of hypoglycemic events per 30 days between two visits is defined as the total number of events between the visits divided by the actual number of days between the visits, and then multiplied by 30 days. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.
| hypoglycemic events per 30 days | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Total Hypoglycemia with BG ≤70 mg/dL | 1.75 ± 2.00 | 1.83 ± 2.32 |
| Severe Hypoglycemia | 0.00 ± 0.05 | 0.00 ± 0.01 |
| Nocturnal Hypoglycemia with BG ≤70 mg/dL | 0.61 ± 0.96 | 0.66 ± 1.20 |
| percentage of participants | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Baseline (n=365, 365) | 5.5 | 3.6 |
| 4 weeks (n=362, 359) | 7.2 | 3.6 |
| 12 weeks (n= 351, 344) | 7.1 | 6.7 |
| 24 weeks (n=337, 328) | 8.6 | 5.8 |
| Endpoint, up to 24 weeks (n= 365, 365) | 8.2 | 6.0 |
| Baseline to 24 weeks (Overall) (n= 365, 365) | 15.3 | 11.0 |
TEAR is defined as an absolute increase of at least 1% in insulin antibody levels (measured in % binding) and at least 30% relative increase from Baseline for participants who are insulin antibody-positive at Baseline, or turning from insulin antibody-negative status at Baseline to antibody-positive during the course of the study following treatment with study drug.
| percentage of participants | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| 4 weeks (n= 362, 359) | 5.0 | 2.8 |
| 12 weeks (n= 351, 344) | 5.1 | 5.2 |
| 24 weeks (n=337, 328) | 6.2 | 5.2 |
| Endpoint, up to 24 weeks (n= 365, 365) | 6.0 | 5.5 |
| Overall (n= 365, 365) | 12.3 | 9.3 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2963016 + OAMs | — | 15/376 (4%) | 188/376 (50%) |
| Lantus + OAMs | — | 18/380 (4.7%) | 175/380 (46.1%) |
| Event | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 1/376 | 3/380 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/376 | 3/380 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/197 | 1/181 |
| Cardiac failure congestiveCardiac disorders | 1/376 | 0/380 |
| Coeliac diseaseGastrointestinal disorders | 1/376 | 0/380 |
| Intestinal obstructionGastrointestinal disorders | 1/376 | 0/380 |
| CholecystitisHepatobiliary disorders | 1/376 | 0/380 |
| BronchitisInfections and infestations | 1/376 | 1/380 |
| CellulitisInfections and infestations | 1/376 | 1/380 |
| Clostridial infectionInfections and infestations | 1/376 | 0/380 |
| Event | LY2963016 + OAMs | Lantus + OAMs |
|---|---|---|
| NasopharyngitisInfections and infestations | 21/376 | 22/380 |
| Upper respiratory tract infectionInfections and infestations | 19/376 | 15/380 |
| DiarrhoeaGastrointestinal disorders | 9/376 | 14/380 |
| InfluenzaInfections and infestations | 7/376 | 11/380 |
| Abnormal weight gainMetabolism and nutrition disorders | 10/376 | 3/380 |
| Back painMusculoskeletal and connective tissue disorders | 9/376 | 10/380 |
| NauseaGastrointestinal disorders | 8/376 | 8/380 |
| SinusitisInfections and infestations | 8/376 | 3/380 |
| HeadacheNervous system disorders | 8/376 | 6/380 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/376 | 8/380 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | LY2963016 + OAMs | Lantus + OAMs | Total |
|---|---|---|---|
| Mean | 58.98 ± 10.17 | 58.67 ± 10.02 | 58.82 ± 10.09 |
| Sex: Female, Male(Participants) | LY2963016 + OAMs | Lantus + OAMs | Total |
|---|---|---|---|
| Female | 197 | 181 | 378 |
| Male | 179 | 199 | 378 |
| Ethnicity (NIH/OMB)(Participants) | LY2963016 + OAMs | Lantus + OAMs | Total |
|---|---|---|---|
| Hispanic or Latino | 106 | 104 | 210 |
| Not Hispanic or Latino | 244 | 256 | 500 |
| Unknown or Not Reported | 26 | 20 | 46 |
| Race (NIH/OMB)(Participants) | LY2963016 + OAMs | Lantus + OAMs | Total |
|---|---|---|---|
| American Indian or Alaska Native | 17 | 21 | 38 |
| Asian | 29 | 35 | 64 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 26 | 32 | 58 |
| White | 302 | 291 | 593 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | LY2963016 + OAMs | Lantus + OAMs | Total |
|---|---|---|---|
| Czech Republic | 18 | 18 | 36 |
| France | 8 | 8 | 16 |
| Germany | 15 | 13 | 28 |
| Greece | 10 | 12 | 22 |
| Hungary | 32 | 30 | 62 |
| Italy | 6 | 5 | 11 |
| Korea, Republic of | 17 | 15 | 32 |
| Mexico | 29 | 29 | 58 |
| Poland | 12 | 11 | 23 |
| Puerto Rico | 39 | 31 | 70 |
| Spain | 10 | 12 | 22 |
| Taiwan | 9 | 12 | 21 |
| United States | 171 | 184 | 355 |
| Baseline Hemoglobin A1c (HbA1c)(percentage of glycosylated hemoglobin) | LY2963016 + OAMs | Lantus + OAMs | Total |
|---|---|---|---|
| Mean | 8.34 ± 1.09 | 8.31 ± 1.06 | 8.33 ± 1.08 |
| Sulfonylurea Use(participants) | LY2963016 + OAMs | Lantus + OAMs | Total |
|---|---|---|---|
| Yes, did use sulfonylurea | 315 | 315 | 630 |
| No, did not use sulfonylurea | 61 | 65 | 126 |
| Time of Basal Insulin Injection(participants) | LY2963016 + OAMs | Lantus + OAMs | Total |
|---|---|---|---|
| Daytime | 187 | 188 | 375 |
| Evening/Bedtime | 189 | 192 | 381 |
1 further baseline measures are reported on the registry.
The record gives a start of Sep 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 2 years 1 month after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine